Certainly, the procedure is not intended just for siblings. If this first case was with an HLA identical sibling, so be it. I am, however, beginning to wonder if either BTRN or MEDI is the least interested in testing the special attributes of 507 as described by Dumont, Bazin and others. Both companies seem content to just use it as a hammer.
Speaking of which, here's a new study using the rat MAb from which 507 was derived.......
Immunol Lett 1999 Jun 1;68(2-3):229-35
Apoptosis of human naive NK cells mediated by a rat IgG2b anti CD2 mAb
through a fractricidal ADCC reaction.
Nizet Y, Chentoufi AA, Havaux X, Kinet I, Cormont F, Bazin H, Latinne D
Experimental Immunology Unit, Faculty of Medicine, University of Louvain, Brussels, Belgium. latinne@imex.ucl.ac.be
[Medline record in process]
LO-CD2a/BTI-322, a rat anti human CD2 mAb, shows in vitro and in vivo immunosuppressive properties and induces T-cell
depletion resulting partially from an antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells. The aim of this
paper is to study the in vitro effect of LO-CD2a/BTI-322 on NK cells, the majority of them also expressing the CD2 molecule.
The addition of the mAb to purified naive NK cells induces apoptosis of CD2+ cells. The apoptosis is rapid, Fas ligand
independent and completely inhibited by the calcium chelator EGTA, suggesting a fractricidal ADCC reaction and implying that
NK cells are not resistant to lysis when used as target cells. At the end of the reaction, the CD2 - remaining cells are still
capable of natural cytotoxicity against K562 cells, but at a lower rate than untreated cells. |
